From this systematic review, we can conclude that the following pharmacogenomic parameters have a significant influence on VIPN in children with cancer: SNPs in ABCB1, ABCC1, ABCC2, CYP3A4, GSTM1, VDR, ACTG1, CAPG, CEP72, MAPT, SYNE2, TUBB2B, SLC5A7, BAHD1, COCH, chromosome 12/chemerin, ETAA1, MRPL4, MTNR1B, NDUFAF6, TMEM215 and in three miRNAs. The gene discussed is MAPT; the disease is cancer.